Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2021 | Novel agents for consolidation after auto-SCT in myeloma

Nico Gagelmann • 16 Mar 2021
EBMT 2021
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Lenalidomide

Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, gives an overview of novel agents for consolidation after autologous stem cell transplantation (auto-SCT) for patients with myeloma. Dr Gagelmann highlights data from a study investigating lenalidomide, dexamethasone and bortezomib, and data from a study investigating quadruplet therapy with daratumumab and an immunomodulatory drug, commenting on the need for longer follow-up. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

More from Nico Gagelmann

0:52
How CAR-T will impact the future of myeloma treatment
Nico Gagelmann • 15 Feb 2024
1:22
The role of splenic irradiation in transplant for patients with myelofibrosis
Nico Gagelmann • 15 Feb 2024
1:41
Predicting outcomes in patients with R/R MM undergoing CAR T-cell therapy: the MyCARe model
Nico Gagelmann • 15 Feb 2024
2:03
Looking to the future in the field of transplantation
Nico Gagelmann • 9 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals